Virpax Pharmaceuticals Inc. (VRPX) saw an uptrend of 6.84% in the recent trading with $4.53 being its most recent. The current price level -87.42% lower than the highest price of $36.00 marked by the stock while trading over the past 52-weeks, whereas it is 22.43% higher than the lowest price of $3.70 the company dropped to over past 52-weeks. The latest news story on VRPX appeared in Business Wire under the title “Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar” on Oct-06-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -60.47% below one month high and is +9.42% above of the lowest during that time. Looking into the simple moving average, Virpax Pharmaceuticals Inc. (VRPX)’s stock stands at a SMA-50 of $9.30 while that of 5-day is reading $4.35.
Virpax Pharmaceuticals Inc. Earnings – What Happened With VRPX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
VRPX – Virpax Pharmaceuticals Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 4.96 million. VRPX does have institutional investors; and they hold 26.70% of the stock.
Virpax Pharmaceuticals Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, VRPX declared 0 shares have been sold in 0 insider transactions over the past three months.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Virpax Pharmaceuticals Inc. was 0.02 while posting a debt to equity ratio of 0.15.